Research progress of CCR8 in tumor immunotherapy
10.19401/j.cnki.1007-3639.2024.03.008
- VernacularTitle:CCR8在肿瘤免疫治疗中的研究进展
- Author:
Yifan CHEN
1
;
Ting LI
;
Biyun WANG
Author Information
1. 复旦大学附属肿瘤医院乳腺及泌尿肿瘤内科,复旦大学上海医学院肿瘤学系,上海 200032
- Keywords:
Tumor;
CC chemokine receptor 8;
Immunotherapy;
Targeted therapy
- From:
China Oncology
2024;34(3):299-305
- CountryChina
- Language:Chinese
-
Abstract:
Therapies for tumors continue to develop,and tumor immunotherapy has emerged as an effective means of controlling tumor progression.Given the limitations of immunotherapy,only some specific patients can benefit from immunotherapy.Since the complex tumor microenvironment is highly influenced by individual variability,immunotherapy will be subjected to different degrees of immune suppression in different tumor microenvironments and thus cannot exert its full effect.In the tumor microenvironment,regulatory T(Treg)cell plays as an immunosuppressive role.Numerous Treg cells infiltrate in indifferent tumor types,resulting in immune escape of tumor tissues,which will have a negative impact on treatment and prognosis.CC chemokine receptor 8(CCR8)belongs to the CC chemokine receptor family.CCR8 is specifically expressed on Treg cell in the tumor microenvironment and expressed at low level in the surrounding normal tissues and peripheral blood thus it can be a specific marker for Treg cell.CCR8 is a potential therapeutic target and biomarker.This review summarized the research progress of CCR8 in different tumor types in recent years,so as to provide reference for subsequent research.
